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Although the COVID-19 pandemic has left no country untouched there has been limited
research to understand clinical and immunological responses in African populations. Here we
characterise patients hospitalised with suspected (PCR-negative/IgG-positive) or confirmed
(PCR-positive) COVID-19, and healthy community controls (PCR-negative/IgG-negative).
PCR-positive COVID-19 participants were more likely to receive dexamethasone and a
beta-lactam antibiotic, and survive to hospital discharge than PCR-negative/IgG-positive and
PCR-negative/IgG-negative participants. PCR-negative/IgG-positive participants exhibited a
nasal and systemic cytokine signature analogous to PCR-positive COVID-19 participants,
predominated by chemokines and neutrophils and distinct from PCR-negative/IgG-negative
participants. PCR-negative/IgG-positive participants had increased propensity for
Staphylococcus aureus and Streptococcus pneumoniae colonisation. PCR-negative/IgG-positive
individuals with high COVID-19 clinical suspicion had inflammatory profiles analogous to
PCR-confirmed disease and potentially represent a target population for COVID-19 treatment
strategies.
https://doi.org/10.1038/s41467-021-23267-w OPEN
1Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi. 2 Department of Clinical
Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. 3 Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. 4 Institute of Infection,
Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. 5 Harvard School of Public Health, Boston, MA, USA. 6 Broad Institute of MIT and
Harvard, Cambridge, MA, USA. 7 University of Glasgow MRC Centre for Virus Research, Glasgow, UK. 8University of Malawi-College of Medicine,
Blantyre, Malawi. 9 Department of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi. 12These authors contributed equally: Ben Morton, Kayla G.
Barnes, Jennifer Cornick, Kondwani C. Jambo. *A list of authors and their affiliations appears at the end of the paper. ✉email: ben.morton@lstmed.ac.uk;
Kondwani.Jambo@lstmed.ac.uk









The coronavirus disease 2019 (COVID-19) pandemic has, todate, been less severe in sub-Saharan Africa compared toEurope and the Americas1. However, clinical diagnosis,
triage and treatment decisions for COVID-19 patients is parti-
cularly challenging in resource-poor settings. The increased
transmissibility of new severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2) variants observed in the second wave
of the pandemic has made the need to address these challenges
even more urgent2. Limited access to advanced life-preserving
therapies such as mechanical ventilation, and delayed presenta-
tion to hospital, is common3. This increases clinical and diag-
nostic complexity as patients may present when severely unwell,
and potentially, without polymerase chain reaction (PCR)-
detectable SARS-CoV-2 (ref. 4).
Cytokine dysregulation has been consistently observed in
COVID-19 patients in multiple settings5,6. Consequently, cyto-
kines, including interleukin-6 (IL-6) and tumour necrosis factor-α
(TNF-α), have shown potential prognostic value to guide deci-
sions on clinical management of COVID-19 (refs. 7,8), but they
lack adequate specificity. For example, IL-6 levels may be 10- to
200-fold higher for patients with the hyperinflammatory pheno-
type of acute respiratory distress syndrome (ARDS) compared to
patients with severe COVID-19 (ref. 9). Beyond the use of single
markers, systems approaches have demonstrated immune sig-
natures distinct to COVID-19 aligned with disease severity10–12.
They have identified a systemic immune signature showing
profoundly altered T cells, selective cytokine/chemokine
upregulation10 and monocyte and neutrophil activation in hos-
pitalised COVID-19 patients11,12. Further, inflammatory dysre-
gulated IL-2, IL-6, IL-10 and IL-15 are associated with COVID-
19-related mortality13. However, there are very few studies that
have investigated the respiratory tract, the initial site of infection
and disease pathogenesis.
SARS-CoV-2 infection is established when the virus binds to
angiotensin-converting enzyme 2 (ACE2)-expressing epithelial
cells in the nasal mucosa14. The few studies reporting mucosal
cellular or cytokine responses in COVID-19 have shown cytokine
dysregulation and immune cell disruption in the lower airway,
correlating with disease severity15,16. However, there is a paucity
of information on immune responses against SARS-CoV-2
infection in the upper airway17. Minimally invasive sampling
techniques of the nasal mucosa are well tolerated, and highly
useful in human challenge models of respiratory syncytial virus
and Streptococcus pneumoniae18,19. Given importance of the nose
in SARS-CoV-2 infection20, understanding the host–viral inter-
action at the nasal mucosa could provide additional insights to
understand and potentially modulate COVID-19 prognosis.
Immunological responses against SARS-CoV-2 infection at the
nasal mucosa are still poorly understood. Here, we analysed nasal
mucosa and peripheral blood samples from a cohort of patients
admitted to hospital with suspected and/or confirmed COVID-
19. These patients were compared with adult healthy community
controls. Immunological parameters were studied using 38-
multiplex cytokine assays and flow cytometry, while profiling of
respiratory pathogens was done using a 33-multiplex polymerase
chain reaction (PCR) respiratory pathogen diagnostic panel. Our
study provides insights on the cytokine responses in the nasal
mucosa following SARS-CoV-2 infection in severe COVID-19
patients and the potential importance of additional confirmatory
antibody tests for diagnosis of SARS-CoV-2 PCR-negative
patients with high clinical suspicion of COVID-19.
Results
Clinical overview. Between 21 April 2020 and 25 September
2020, 87 patients (median age 47 years, IQR: 34–62) presenting
with severe acute respiratory infection (SARI) were recruited, of
whom 60 (69.0%) were male (Table 1). SARS-CoV-2 was con-
firmed by nucleic acid amplification (NAAT) in 41 participants
(classified as “PCR-confirmed COVID-19”) (Fig. 1a). The
remaining 46 participants with suspected disease were NAAT
negative (Fig. 1a). Of these, 25 were IgG positive against spike
protein 2 and nucleoprotein on serological testing. Using
NAAT and antibody test results, we reclassified the patient
groups into PCR-confirmed COVID-19, PCR−/IgG+ SARI
Table 1 Clinical characteristics.




P value Healthy control
(n= 24)
Male n (%) 30 (73) 18 (72) 12 (57) 0.455a 20 (83)
Age median (IQR) 50 (42–65) 34 (25–51) 41 (37–60) 0.027b 23 (22–25)
Days from symptom onset to hospital
admission
median (IQR) 4 (2–7) 6 (2–13) 4 (3–14) 0.814b NA
Days from hospital admission to
research sample
Median (IQR) 4 (3–6) 3 (1–4) 1 (1–2) 0.003b NA
HIV seropositive n (%) 9 (31c) 9 (45c) 9 (64c) 0.110a 0 (0)
TB positive n (%) 1 (2) 0 (0) 0 (0) 1.000a 0 (0)
Malaria positive n (%) 2 (5c) 1 (5c) 0 (0c) 0.157a 0 (0)
Cardiac disease n (%) 13 (36c) 5 (25c) 3 (14) 0.204a 0 (0)
Pulmonary disease n (%) 3 (9c) 0 (0c) 0 (0c) 0.433a 0 (0)
Oxygen required at enrolment n (%) 21 (54c) 12 (48) 10 (50c) 0.886a 0 (0)
ISARIC 4C clinical severity score Median (IQR) 5 (4–8) 4 (3–7) 6 (5–8) 0.075b 0 (0–0)
UVA score Median (IQR) 2 (0–4) 2 (1–3) 4 (2–5) 0.025b 0 (0–0)
Beta-lactam antibiotic administered n (%) 32 (78) 13 (52) 10 (48) 0.022a NA
Steroids administered n (%) 26 (63) 1 (4) 0 (0) <0.001a NA
Died in hospital n (%) 3 (7c) 5 (20c) 9 (43c) 0.009a NA
Hospital length of stay for survivors Median (IQR) 8 (6–17) 6 (4–9) 6 (3–8) 0.028b NA
PCR+ is RT-qPCR confirmed SARS-CoV-2 severe acute respiratory infection (SARI); PCR−/IgG− is patients with SARI who were RT-qPCR negative but IgG positive for SARS-CoV-2; and PCR−/IgG− is
patients with SARI who were both RT-qPCR negative and IgG negative for SARS-CoV-2. Healthy controls were ambulant patients with no intercurrent illness who attended an outpatient clinic
appointment. ISARIC 4C score calculated using six clinical variables available within dataset as urea and C-reactive protein were not available. UVA universal vital assessment score (low-income country
validated clinical severity score).
aFisher’s exact test.
bKruskall–Wallis test.
cProportion (%) positivity calculated using the denominator for individual variables (unknown status classified as missing data).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23267-w
2 NATURE COMMUNICATIONS |         (2021) 12:3554 | https://doi.org/10.1038/s41467-021-23267-w |www.nature.com/naturecommunications
(n= 25) and PCR−/IgG− SARI (n= 21) participants (Fig. 1b).
In addition, we recruited 25 ambulatory healthy volunteers.
Patient demographics and clinical characteristics are reported in
Table 1. To verify the specificity of the ELISA assay, we tested
pre-COVID-19 pandemic historical sera from individuals with
other coronaviruses, malaria convalescent sera, sera from people
living with HIV and sera from asymptomatic HIV-uninfected
adults, and found a specificity of 8/132 (94% [CI 91–97]) (Sup-
plementary Fig. 1). We also tested antibodies in a WHO-
recommended NIBSC Proficiency Plasma Panel (20/120, 20/122,
20/124, 20/126, 20/128 and 20/130) and found 100% concordant
results (Supplementary Fig. 1). Hospitalised individuals with
PCR-confirmed COVID-19 were significantly older (median 50
[PCR+] vs. 34 [PCR−/IgG+] vs. 41 [PCR−/IgG−], p= 0.017),
more likely to have received dexamethasone (63% vs. 4% vs.
0%, p < 0.001) and more likely to have received a beta-lactam
antibiotic (78% vs. 52% vs.48%, p= 0.022) compared to the
PCR−/IgG+ and PCR−/IgG− SARI participants. Additionally,
PCR-confirmed COVID-19 participants were more likely to
survive (93% vs. 80% vs. 57%, p= 0.004) with increased
hospital length of stay (median days 8 vs. 6 vs. 6, p= 0.028)
compared to the PCR−/IgG+ and PCR−/IgG− SARI partici-
pants. PCR−/IgG+ SARI participants also tended toward longer
times from symptom onset to hospital admission compared to
PCR-confirmed COVID-19 participants (median 6 vs. 4 days)
(Table 1).
Distinct cytokine responses induced by SARS-CoV-2 infection
in nasal mucosa and systemic circulation. We investigated the
cytokine response in nasal lining fluid and serum of our four
participant groups. Our analysis was limited to 25 PCR-
confirmed COVID-19 participants (who were IgG positive),
16 PCR−/IgG+ SARI participants, 11 PCR-/IgG- SARI partici-
pants and 25 healthy controls, from whom we had paired nasal
lining fluid and serum samples. We measured the concentration
of 37 cytokines (and sCD40L) in paired nasal lining fluid and
serum samples of the four study groups (Supplementary Fig. 2
and Supplementary Fig. 3). We found altered cytokine levels in
both nasal lining fluid and serum of PCR-confirmed COVID-19
participants, PCR−/IgG+ SARI participants and PCR−/IgG−
SARI participants, relative to healthy controls (Fig. 2). Specifi-
cally, high concentrations of inflammation-related cytokines were
common among all the patient groups compared to healthy
controls, including IL-1α, IL-1β, IL-6, MIP-1α and TNF-α in
nasal lining fluid, and raised levels of IL-6, IL-10, IP-10 and IL-15
in serum. Relative to healthy controls, low levels of IL-4, IL-1RA,
GRO and VEGF, and high levels of IL-2 in nasal lining fluid, were
confined to PCR-confirmed COVID-19 and PCR−/IgG+ SARI
participants (Fig. 2). While in serum, low levels of EGF, Flt-3L,
MDC and IL-12p70 in serum were distinctive to PCR-confirmed
COVID-19 and PCR-/IgG+ SARI participants. In addition, IL-3
levels were distinctively high in nasal lining fluid and serum of
PCR-confirmed COVID-19 and PCR−/IgG+ SARI participants,
relative to healthy controls (Fig. 2 and Supplementary Figs. 2 and
3). The results demonstrate SARS-CoV-2 infection induces a
distinct cytokine response in the nasal mucosa compared to
systemic circulation. This also suggests that PCR-confirmed
COVID-19 and PCR−/IgG+ SARI participants may be pre-
senting at different stages of the SARS-CoV-2 infection spectrum.
Severe COVID-19 is associated with a distinct nasal and serum
cytokine profile to non-COVID-19 SARIs. Due to the similarity
of the cytokines induced in PCR−/IgG+ SARI participants
relative to PCR-confirmed COVID-19 (Fig. 2), coupled with
clinical manifestations of COVID-19 (Table 1), and the positive
SARS-CoV-2 IgG serology result (Fig. 1b), we explored if clinical
reclassification of PCR−/IgG+ SARI participants as COVID-19
disease was warranted. We hypothesised that using an unsu-
pervised analysis the immunological phenotype of PCR−/IgG+
SARI participants would be analogous to PCR-confirmed
COVID-19 participants, but distinct from PCR−/IgG− SARI
participants and healthy controls. First, we performed a principal
component analysis (PCA) of all the analytes for the patients and
controls in either nasal lining fluid and serum. In both com-
partments, PCA segregated together PCR-confirmed COVID-19
participants and PCR−/IgG+ SARI participants, away from
healthy controls, whereas PCR−/IgG− SARI participants showed
major overlap with the other groups (Fig. 3a, b). The cytokines
that contributed to the clustering of the study groups away from
the controls were IL-6, IL-4, IL-3, MIP-alpha, G-CSF, IL-1beta in
nasal samples and IL-3, IL-6, Flt-3L, EGF, IFN-gamma, IL-5, IL-
12p70, IP-10, IL-10, IL12p40 in serum. Second, we analysed the
active cytokine functional families in nasal and serum, to ascer-
tain whether PCR−/IgG+ SARI participants had immunological
pathways similar to PCR-confirmed COVID-19 participants.
Analysis of the active cytokine functional families has previously
been used to define immune signatures unique to COVID-
1910–12. To aid interpretation of the data, the cytokines were
divided into functional groups, including growth factors, che-
mokines, adaptive, pro-inflammatory and anti-inflammatory. In
both nasal lining fluid and serum, differential interaction of
cytokines was observed among the study groups, with the
cytokine interaction profile being generally similar between
PCR−/IgG+ SARI participants and PCR-confirmed COVID-19
participants, but distinct from PCR−/IgG− SARI participants
and healthy controls (Fig. 3c, d). Specifically, in the nasal
lining fluid, we observed a strong interaction in the chemokine
family, including between chemokines and growth factors, in
PCR-confirmed COVID-19 participants and PCR−/IgG+ SARI
participants (Fig. 3c). In the serum, fewer interactions were
Fig. 1 Study recruitment timeline and SARS-CoV-2 diagnosis. a Suspected
and SARS-CoV-2 RT-qPCR-confirmed COVID-19 patients recruited at
Queen Elizabeth Central Hospital, Blantyre (positive (red) and negative
(blue)) reported as cases/week compared to the national data (light grey).
National data include SARS-CoV-2 RT-qPCR-confirmed symptomatic and
non-symptomatic COVID-19. b SARS-CoV-2 Spike protein 2 (S2) and
nucleoprotein (NP) IgG antibodies in PCR-negative and -positive
individuals. The data are reported as the ratio of OD in the test samples to
the assay threshold control. For all boxplots, box boundaries correspond to
25th and 75th percentiles; whiskers extend to a maximum or minimum
greatest value. Data were analysed using Mann–Whitney test, two-sided
(PCR positive, n= 38; PCR negative, n= 45). SARS-CoV-2 severe acute
respiratory syndrome coronavirus 2, COVID-19 coronavirus disease of
2019, PCR polymerase chain reaction, IgG immunoglobulin, SARI severe
acute respiratory infection. Source data are provided as a Source Data file.
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observed, but still a distinct pattern in the adaptive cytokine
family in PCR-confirmed COVID-19 participants and PCR−/
IgG+ SARI participants (Fig. 3d). Third, in a subset of partici-
pants, we explored the nasal immune cellular profile in PCR-
confirmed COVID-19 and PCR−/IgG+ SARI participants com-
pared to healthy controls using flow cytometry (gating strategy,
Supplementary Fig. 4). We observed a higher frequency of neu-
trophils and lower frequency of CD3+ T cells in the nasal mucosa
of PCR-confirmed COVID-19 and PCR−/IgG+ SARI partici-
pants compared to healthy controls (Fig. 4). Collectively, the
findings demonstrate that the PCR−/IgG+ SARI participants
induced similar immunological pathways to PCR-confirmed
COVID-19 participants, but that this was distinct from PCR−/
IgG− SARI participants. Taken together, these findings
suggest that clinical reclassification of COVID-19 status could be
warranted.
PCR-confirmed COVID-19 participants exhibit reduced pro-
pensity for bacterial colonisation. Due to the differential clinical
management pathways experienced by the PCR-confirmed
COVID-19 and PCR−/IgG+ SARI participants in the study,
including beta-lactam antibiotic usage and steroid treatment, we
sought to determine the presence of other respiratory pathogens
in NP/throat swabs. Bacterial co-infection with SARS-CoV-2 is
associated with adverse outcomes21,22. A total of 80 participants
from the patient groups (from whom we had complete clinical
and antibody data) were tested for the presence of respiratory
pathogens using the fast-track diagnostics (FTD)-33 respiratory
panel. The median time from admission to NP/throat swab col-
lection for the respiratory panel testing was 3 days (IQR 1–5).
Using the FTD-33 panel we identified 12 other respiratory
pathogens present in our patient population, in addition to SARS-
CoV-2 and HIV (Fig. 5a). Overall, 74% (59/80) of participants
had one or more pathogen(s) (Fig. 5a). The presence of bacterial
pathogens was common, identified in 74% (59/80), but viral
pathogens (excluding HIV) were only present in 14% (11/80)
of participants (Fig. 5a and Supplementary Fig. 5a). The most
common respiratory pathogen across all study groups was Kleb-
siella pneumoniae (Supplementary Fig. 5a). A total of 27/44 of the
participants with a K. pneumoniae had received ceftriaxone or
amoxicillin within 24 h of admission, suggesting that this was
Fig. 2 Cytokine concentrations in nasal lining fluid and serum. Volcano plots showing differential cytokine concentrations in nasal lining fluid and serum of
PCR-confirmed COVID-19, PCR−/IgG+ SARI and PCR−/IgG− SARI patients compared to health controls. The horizontal dotted line represents a cut-off for
statistical significance, while the vertical dotted line represents a cut-off point for determining whether the levels of the cytokines were higher (right, red) or
lower (left, blue) compared to healthy controls. Data were analysed using empirical Bayes moderated two-sided t-tests and adjusted p values are reported
(healthy controls, n= 25; PCR-confirmed COVID-19, n= 25; PCR−/IgG+ SARI, n= 16; PCR−/IgG− SARI, n= 11). SARS-CoV-2 severe acute respiratory
syndrome coronavirus 2, COVID-19 coronavirus disease of 2019, PCR polymerase chain reaction, IgG immunoglobulin G, SARI severe acute respiratory
infection. Source data are provided as a Source Data file.
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Fig. 3 Nasal and serum cytokine profiles. Principal component analysis (PCA) of the 38 analytes (37 cytokines and sCD40L) in a nasal lining fluid and
b serum of healthy controls, PCR-confirmed COVID-19, PCR−/IgG+ SARI and PCR−/IgG− SARI patients, showing similarity of nasal cytokine responses
between PCR-confirmed COVID-19 and PCR−/IgG+ SARI patients. Correlogram of cytokine interactions in c nasal lining fluid and d serum among the
different study groups, showing induction of similar immune process in PCR-confirmed COVID-19 and PCR−/IgG+ SARI patients. For all boxplots, box
boundaries correspond to 25th and 75th percentiles; whiskers extend to a maximum of 1.5× the interquartile range, with values outside the box and
whiskers being outliers. Healthy controls, n= 25; PCR-confirmed COVID-19, n= 25; PCR−/IgG+ SARI, n= 16; PCR−/IgG− SARI, n= 11. SARS-CoV-2
severe acute respiratory syndrome coronavirus 2, COVID-19 coronavirus disease of 2019, PCR polymerase chain reaction, IgG immunoglobulin G, SARI
severe acute respiratory infection, PC1 principal component 1, PC2 principal component 2. Source data are provided as a Source Data file.
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Fig. 4 Nasal cell composition in healthy controls, confirmed and suspected COVID-19 patients. a Representative flow cytometry plots for cellular
composition in the nasal mucosa of healthy controls, PCR-confirmed COVID-19 and PCR−/IgG+ SARI patients. b Proportions of T cells, B cells, neutrophils
and monocytes in nasal mucosa of healthy controls and COVID-19 patients. For all boxplots, box boundaries correspond to 25th and 75th percentiles;
whiskers extend to a maximum or minimum greatest value. Data were analysed using Kruskal–Wallis test, two-sided (healthy controls, n= 20; PCR-
confirmed COVID-19, n= 20; PCR−/IgG+ SARI, n= 11). SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, COVID-19 coronavirus disease of
2019, PCR polymerase chain reaction, IgG immunoglobulin G, SARI severe acute respiratory infection. Source data are provided as a Source Data file.
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likely a hospital-acquired multidrug resistant (MDR) K. pneu-
moniae. MDR K. pneumoniae is known to be endemic at Queen
Elizabeth Central Hospital23. Furthermore, we observed differ-
ences between PCR-confirmed COVID-19 and PCR−/IgG+
SARI participants. The PCR-confirmed COVID-19 participants
had lower prevalence rates of Staphylococcus aureus (3/38
[8%] vs. 6/24 [25%], p= 0.018) and tended toward lower Strep-
tococcus pneumoniae (8/38 [21%] vs. 10/24 [42%], p= 0.071)
Fig. 5 Co-colonisation/infection status of suspected and confirmed COVID-19 patients. a Profile of co-colonisation/infection pathogens in
nasopharyngeal/throat swabs. Prevalence of b Staphylococcus aureus and c Streptococcus pneumoniae co-colonisation in suspected and confirmed COVID-19.
The horizontal bars represent the median and interquartile range (IQR). Data were analysed using Kruskal–Wallis test (PCR-confirmed COVID-19, n= 39;
PCR−/IgG+ SARI, n= 23; PCR−/IgG− SARI, n= 22). COVID-19 coronavirus disease of 2019. Source data are provided as a Source Data file.
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than PCR−/IgG+ SARI participants (Fig. 5b, c). These findings
show that presence of bacterial pathogens in the upper respiratory
tract was very common in our hospitalised patient cohort. They
also show that PCR-confirmed COVID-19 patients had lower
proclivity for S. aureus and S. pneumoniae colonisation than
PCR−/IgG+ SARI participants, potentially impacted by
increased use of beta-lactam antibiotic usage in this study group.
Association of HIV co-infection with cytokine responses,
respiratory bacterial prevalence and clinical outcomes in COVID-
19 patients. In our cohort, people living with HIV were distributed
across the patient groups (Table 1). We therefore explored the
influence of HIV co-infection on the cytokine responses, presence of
respiratory pathogens and mortality. We reclassified the PCR−/IgG+
SARI participants as COVID-19 and combined them with the PCR-
confirmed COVID-19 to form a single COVID-19 patient group.
There were no statistically significant differences in the levels of
cytokines in nasal lining fluid and serum between HIV-infected and
HIV-uninfected COVID-19 participants (Fig. 6a, b). Furthermore, we
did not observe increased frequency of respiratory pathogens in NP/
throat swab nor higher mortality (Fisher’s exact test, p= 0.277) in
HIV-infected compared to HIV-uninfected COVID-19 participants
(Fig. 5b, c and Supplementary Fig. 5b). Together, in our cohort, we
did not find evidence suggestive that HIV co-infection in COVID-19
participants was associated with altered cytokine responses, increased
prevalence of respiratory pathogens nor increased mortality. It is
important to state that our study was not explicitly powered to detect
differences between HIV-infected and HIV-uninfected individuals
and that this is an exploratory analysis that requires validation in
future studies.
Discussion
We provide clinical and immunological analysis of suspected or
confirmed COVID-19 patients admitted to hospital in Malawi, a
low-income sub-Saharan African country. We identified indivi-
duals with SARI and manifestations of COVID-19 who were
SARS-CoV-2 RT-qPCR negative but IgG positive that showed
immunological profile analogous to PCR-confirmed COVID-19
participants. This was distinct from PCR−/IgG− SARI partici-
pants and healthy controls. The PCR−/IgG+ SARI subgroup
experienced poorer clinical outcomes compared to PCR-
confirmed participants, potentially due to later hospital pre-
sentation, failure to access effective treatment for COVID-19 or
superadded bacterial infections. In our cohort, access to drugs
such as dexamethasone in patients suspected of COVID-19 was
determined by RT-qPCR test positivity and not SARS-CoV-2 IgG
antibody status. Identification of this subgroup of SARI patients
highlights the importance for further optimisation of triage and
clinical treatment pathways in the era of COVID-19, especially in
low-resource settings.
Low cost, effective and pragmatic interventions such as dex-
amethasone have been widely adopted and incorporated into
treatment pathways24. The COVID-19 treatment guidelines
recommend against dexamethasone administration for patients
who do not require supplemental oxygen25 but there are no
specific recommendations for how COVID-19 should be diag-
nosed. The RECOVERY dexamethasone trial24 that showed
efficacy in hospitalised COVID-19 patients included patients with
“clinically suspected” or laboratory confirmed SARS-CoV-2
infection. The PCR−/IgG+ SARI subgroup could potentially fit
into this “clinically suspected” COVID-19 classification. Empiri-
cal antibiotics are recommended for severe COVID-19 patients if
co-existing bacterial pneumonia cannot be excluded26. Consistent
with this recommendation, there was increased beta-lactam
antibiotic usage in PCR-confirmed COVID-19 participants who
demonstrated a lower prevalence of S. pneumoniae and S. aureus
colonisation. The PCR−/IgG+ participants did not access these
standardised clinical management strategies and may be at a
disadvantage compared to PCR-confirmed patients, with whom
they share analogous immunological profiles, potentially putting
the patients at increased risk of poor prognosis. Well conducted
interventional trials are required to determine if this important
subgroup could benefit from diagnostic reclassification and
treatment as COVID-19.
Cytokine dysregulation is a hallmark of severe COVID-19
(ref. 27). Consistent with published studies5,6, we observed high
concentrations of inflammation-associated cytokines, including
IL-6, TNF-α, IP-10, IL-10, IL-1α and IL-1β, in serum and nasal
lining fluid from PCR-confirmed COVID-19 patients. However,
elevation of these cytokines was also observed in serum from
non-COVID SARI participants. Instead, the induction of the
chemokine family in the nasal mucosa was distinctive to severe
COVID-19 and was distinct from systemic circulation. The pre-
dominance of the chemokine family was in line with the infil-
tration of neutrophils in the upper airway observed in this cohort
and others28,29. A study that performed transcriptomic analysis
Fig. 6 Cytokine concentrations in nasal lining fluid and serum based on
HIV-co-infection status. PCR-confirmed COVID-19 and PCR−/IgG+ SARI
patients were combined (n= 41) into one COVID-19 patient group. Only
cytokines that showed differential responses between patients with healthy
controls were included in the analysis. a Cytokine concentrations between
HIV-infected and uninfected COVID-19 patients in nasal lining fluid.
b Cytokine concentrations between HIV-infected and uninfected COVID-19
patients in serum. The horizontal bars represent the median (blue line) and
interquartile range (IQR) (black lines). Data were analysed using
Kruskal–Wallis test (HIV−, n= 20; HIV+, n= 10). COVID-19 coronavirus
disease of 2019, PCR polymerase chain reaction, SARI severe acute
respiratory infection. Source data are provided as a Source Data file.
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on paired upper and lower respiratory tract samples from two
COVID-19 patients and showed very high congruency in the
majority of the cell types between the sites28, suggesting a shared
immune response between the sites. Consistent with this sug-
gestion, the chemokine-dominated signature and neutrophil
infiltration observed in the upper airway of severe COVID-19
patients in our study was similar to that reported in the lower
airway15,16,30. Neutrophils promote inflammation and play a
pathogenic role in COVID-19 (ref. 31). Circulating neutrophils
from severe COVID-19 patients show exaggerated oxidative
burst, NETosis and phagocytosis relative to healthy controls32.
Measurement of dysregulated neutrophil function in the nose was
not possible in this study, but presence of NETs has been reported
in the lungs of deceased severe COVID-19 patients with acute
respiratory distress syndrome (ARDS)33, where they are thought
to drive severe pulmonary complications of COVID-19. In ARDS
patients, low levels of VEGF in the lower airway are a marker of
acute lung injury34, and in our study, severe COVID-19 patients
exhibited distinctively low concentrations of VEGF in nasal lining
fluid. Collectively, this suggests that further investigation to
determine if the nasal mucosa could provide a snapshot of
immunological activity in the lung in patients with COVID-19 is
warranted, as nasal sampling is well tolerated and more easily
accessible than lower airway sampling.
Some of the major features of severe COVID-19 are lympho-
penia and neutrophilia in the systemic circulation35,36. As such,
the neutrophil to lymphocyte ratio has been shown to have
prognostic value, predicting those at high risk of severe disease or
death37. However, the mechanisms behind lymphopenia and
neutrophilia during COVID-19 are still not well understood.
Interestingly, in our study, concentrations of IL-3 and Flt-3L were
distinctively altered in severe COVID-19 participants compared
to non-COVID-19 SARI participants. Specifically, in severe
COVID-19 participants, IL-3 was detected at very high levels in
the nasal lining fluid, while Flt-3L was repressed in serum. IL-3
and Flt-3L are key cytokines involved in haematopoiesis of
leucocytes38,39. IL-3 induces expansion and generation of myeloid
cells38,39, while Flt-3L binds to Flt-3 and activates common
lymphoid progenitor cells to increase the number of
lymphocytes40,41. Alterations in these cytokines in mouse models
are associated with dysregulated haematopoiesis and altered
leucocyte cellularity39,41. Therefore, it is plausible that high levels
of IL-3 and repressed levels of Flt-3L could contribute to the high
neutrophil to lymphocyte ratio and altered leucocyte numbers
observed in severe COVID-19 patients.
Due to the high HIV prevalence in our setting, we conducted
an exploratory analysis of the impact of HIV co-infection on
COVID-19. While data from the United Kingdom and South
Africa suggests an increased risk of mortality in HIV-infected
COVID-19 patients42–44, a systematic review and data from the
United States did not demonstrate this association45–47. Our
cohort was not powered to detect differences in groups by HIV
status and we did not find statistically significant differences in
the cytokine responses, prevalence of respiratory pathogens nor
mortality between HIV-infected and HIV-uninfected COVID-19
participants. The small sample size of this study limits our ability
to adjust for the multiple potential confounders that could impact
on clinical outcomes, including age, gender, co-morbidities,
antiretroviral therapy status and HIV viral load. Larger cohort
studies with comprehensive immunological data and sufficient
power to adjust for multimorbid diseases are required to provide
further clarity on this issue.
Despite the strengths of this study including use of an inter-
nationally recognised protocol with standardised data collection
tools, well-characterised clinical cohort and paired nasal and
systemic immune responses, our study had some limitations. Due
to programmatic constraints, it was not feasible to conduct
longitudinal sampling among our participants to monitor
recovery and response to therapy. In addition, while the majority
of participants were recruited within the first 72 h of admission, a
proportion of our participants was recruited later in their hospital
admission. This is an important limitation because immunolo-
gical parameters are known to change during the course of
disease and may have been confounded by steroid or antibiotic
use. Our sample size precluded detailed analysis to examine for
confounders. In particular, there were significant differences in
age between the three groups. Lack of critical care facilities pre-
cluded universal recruitment and sampling in the most severe
cases, and our patient population may therefore not be entirely
representative of all participants with SARS-CoV-2-induced
SARI. Furthermore, we cannot exclude secondary bacterial
infections as potential contributors to increased mortality in the
PCR−/IgG+ SARI participants, as we did not have access to
blood culture or autopsy results.
We have demonstrated that SARS-CoV-2 infection induces a
chemokine and neutrophil-dominated profile in the nasal mucosa
different from systemic circulation, and distinct from non-
COVID-19 SARI. We have identified a subgroup of SARS-CoV-2
PCR-negative IgG-positive individuals with clinical and immu-
nological manifestations of COVID-19, who may benefit
from standardised COVID-19 clinical management protocols
(including use of steroids and beta-lactam antibiotics). Further,
operationalisation of sensitive and specific antibody assays for
SARS-CoV-2 IgG detection to support clinical diagnosis needs to
be considered in resource-limited settings. We recommend that
interventional trials should target this clinically important sub-
group of patients to determine if treatment pathways applied
for PCR-confirmed COVID-19 can be implemented safely for
PCR−/IgG+ SARI patients to improve clinical outcomes.
Methods
Study design and recruitment. We prospectively recruited patients using the tier
one sampling strategy from the International Severe Acute Respiratory and
Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol
(CCP)48. Briefly, the CCP is a standardised protocol that enables data and biolo-
gical samples to be collected rapidly in a globally harmonised manner for any
severe respiratory infection of public health interest48. Patients over 18 years old
were approached for informed written consent if they met inclusion criteria: SARI
with suspected or confirmed SARS-CoV-2. We used WHO case definitions for
SARI: history of or measured fever (≥38 °C), cough, onset within last 10 days and
requires hospitalisation49. For patients who lacked capacity, assent was sought from
a proxy as per our ethical approvals. Subsequently, informed consent was obtained
retrospectively from these patients, where possible. Patients were excluded from
recruitment if they or their proxy declined to participate. We aimed to recruit
within 72 h of hospital admission. Nasopharyngeal airway, nasosorption, nasal
biopsy and peripheral blood samples were collected at the point of patient
recruitment. Thereafter, patients were followed up until hospital discharge or
death. All clinical data were collected using REDCap (v9.5.0).
All participants were recruited at Queen Elizabeth Central Hospital (QECH),
Blantyre, Malawi. QECH is a government hospital of 1000 beds, providing free
inpatient medical care to the city of Blantyre (population 800,264), and tertiary care
to those referred from the Southern region (population 7,750,629, 2018). Most
adults present directly to the hospital or are referred from community healthcare
facilities. After triage and testing in dedicated areas, patients with confirmed SARS-
CoV-2 were treated in a cohort ward, including a high dependency area50.
Additionally, patients with SARI were screened for SARS-CoV-2 in two separate
adult medical wards. Context-sensitive standard operating procedures were used to
treat SARS-CoV-2 as detailed in a separate publication51. Invasive mechanical
ventilation, continuous positive airways pressure and high flow oxygen were not
available for SARS-CoV-2 at this institution during this period. Clinical data and
statistical code are available52.
During the period November 2019 to October 2020, we recruited healthy
participants with no acute intercurrent or chronic illness as a healthy control
group. All healthy participants, recruited immediately before (November
2019–March 2020) and after (September 2020–October 2020) the first peak in
Malawi’s reported COVID case count (Fig. 1a), were confirmed as seronegative for
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HIV infection and had no known medical conditions. We incorporated baseline
samples for healthy participants who had volunteered to participate in another
study in this analysis53.
We have complied with all relevant ethical regulations for work with human
participants, and written informed consent was obtained for all participants. The
two study protocols were approved by the Malawi National Health Science
Research Committee (NHSRC, 20/02/2518 and 19/08/2246) and Liverpool School
of Tropical Medicine (study sponsor) Research Ethics Committee (LSTM REC, 20/
026 and 19/017). Patient and health participant samples were anonymised at the
point of sample collection by the research nurses using unique participant
identification barcodes. Study activities were monitored by the Malawi-Liverpool-
Wellcome Trust Clinical Research programme (MLW)’s Clinical Research Support
Unit and we complied with all relevant ethical regulations. Approval for the SARS-
CoV-2 ELISA verification samples was obtained from the College of Medicine
Research Ethics Committee (COMREC, P.05/20/3045).
SARS-CoV-2 PCR diagnostic testing. All participants underwent SARS-CoV-2
testing at hospital admission, and subsequently after study recruitment. After
collection, nasopharyngeal swabs in Universal Transport Medium (UTM) (Copan,
Brescia, Italy) were stored at 7 °C and processed for 2019-nCOV RNA testing
within 48 h, using the CDC 2019-nCoV RNA real-time reverse transcriptase PCR
diagnostic panel (Integrated DNA Technologies, Iowa, USA) or the Da An-RT-
PCR reagent set for 2019-nCoV RNA detection (Da An Gene Co., Ltd of Sun Yat-
Sen University, Guangdong, P.R. China). A cycle threshold (Ct) value of <40 was
considered positive for both assays based on CDC and Da An guidelines using
QuantStudio Real-Time PCR software v1.3 (Applied Biosystems, UK). Both assays
utilise an internal control to identify presence of human RNA (CDC—ribonuclease
Protein, Da An internal control is not published). A negative extraction control and
a PCR no-template control were also performed with every test.
Respiratory fast track diagnostic panel. Aliquots of UTM were stored at −80 °C
and tested in batches using the FTDⓇ Respiratory Pathogens 33 kit (Fast track
Diagnostics Ltd, Luxembourg) as per the manufacturer’s instructions. In brief,
samples were extracted using the QIAamp UCP Pathogen Mini Kit (Qiagen Ltd,
UK) for both DNA and RNA. Each sample was then tested using the RT-qPCR
based FTD panel. This panel includes the following pathogens: parainfluenza
viruses 1, 2, 3 and 4; human coronaviruses NL63, 229E, OC43 and HKU1; human
metapneumoviruses A/B; human rhinovirus; human respiratory syncytial viruses
A/B; human adenovirus; enterovirus; human parechovirus; human bocavirus;
Pneumocystis jirovecii; Mycoplasma pneumoniae; Chlamydophila pneumoniae;
Streptococcus pneumoniae; Haemophilus influenzae B; Staphylococcus aureus;
Moraxella catarrhalis; Bordetella spp.; Klebsiella pneumoniae; Legionella pneumo-
phila/longbeachae; Salmonella spp.; Haemophilus influenzae and internal control.
Ct values <40 were considered positive. Diagnostic data and code are available54.
SARS-CoV-2 IgG enzyme linked-immunosorbent assay. Peripheral blood col-
lected in serum separation tubes underwent centrifugation at 500g for 8 min to
isolate serum. Serum was stored at −80 °C. To measure SARS-CoV-2 antibodies,
we used a CE-marked commercial enzyme linked-immunosorbent assay (ELISA)
targeting Spike (S2) and Nucleoprotein (NP) from SARS-CoV-2 (Omega diag-
nostics, UK; ODL 150/10; Lot #103183). This assay has previously been used in our
context in a published healthcare worker seroprevalence study55. We have also
tested this assay on WHO-supplied NIBSC COVID-19 Convalescent Plasma Panel
(20/120, 20/122, 20/124, 20/126, 20/128 and 20/130) and found 100% concordant
results. The assay was performed as per the manufacturer’s instructions. In brief,
participant serum was diluted (1:200) in sample diluent (150mM Tris-buffered
saline, pH 7.2 with antimicrobial agent). The diluted samples, diluent alone
(negative control), manufacturer’s cut-off control and positive control were added
at 100 μl per well to a plate pre-coated with S2 and NP. The plate was incubated at
room temperature for 30 min. After incubation, the plate was washed three times
with a wash buffer (100 mM Tris-buffered saline with detergent, pH 7.2) using a
plate washer (Asys Atlantis, Biochrom Ltd, UK). One hundred microliters anti-
human IgG conjugated to horseradish peroxidase was then added to each well and
incubated for 30 min at room temperature. After incubation, the plate was washed
four times with a wash buffer, and 100 μl of TMB (3,3′,5,5′-tetramethylbenzidine)
substrate (aqueous solution of TMB and hydrogen peroxide) was added. The plate
was incubated for 10 min at room temperature, before addition of 100 μl of Stop
Solution (0.25 M sulfuric acid). The optical density (OD) of each well was read at
450 nm in a microplate reader (BioTek ELx808, UK) within 10 min of adding the
Stop Solution using Gen 5 software v2.09 (BioTek, UK). The ratio of OD in the test
samples to the assay threshold control was calculated. The assay interpretation was
as follows: positive result (ratio ≥1) and negative result (ratio <1). All serology data
are available56.
Flow cytometry analysis. For immunophenotyping, nasal cells were dislodged
from curettes by pipetting and stained with an antibody cocktail containing anti-
human CD3 APC (2D1, 368514, 1:40) and anti-human CD66b PE (UCHT1,
300439, 1:50) from Biolegend (UK), and anti-human CD45 Alexa Fluor 700
(G10F5, 12-0666-42, 1:80) from eBioscience (UK). Samples were acquired on an
LSR FORTESSA flow cytometer using FACSDIVA (BD Biosciences, UK) and
analysed using Flowjo v10.5.3 (BD Biosciences, USA). All flow cytometry data are
available56.
Luminex analysis of nasal lining fluid. Cytokines were eluted from stored
nasosorption filters (Mucosal Diagnostics, Hunt Developments (UK) Ltd, Mid-
hurst, UK) using 200 μl of elution buffer (Millipore) by centrifugation at 1500g, and
then the eluate was cleared by further centrifugation at 1595g. The samples were
acquired on a MAGPIX (Luminex, UK) using a 38-plex magnetic human cytokine
kit (Millipore) and analysed with xPONENT software following the manufacturer’s
instructions. The analytes included sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3
ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13,
IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, TGF-α,
TNF-α, TNF-β and VEGF. All cytokine data and code are available56.
Statistical analysis. Clinical data were analysed using Stata V15.1 (StataCorp,
Stata Statistical Software: Release 15, College Station, Texas, USA). Categorical
variables were compared using the Fisher’s exact test. Continuous variables were
tested for normality and appropriate statistical tests applied. Non-normally dis-
tributed measurements are expressed as the median and were analysed by the
Kruskal–Wallis test. For the volcano plots, data were analysed using empirical
Bayes moderated t-tests with adjusted p values reported. A p value of <0.05 was
considered statistically significant. Immunological and diagnostic data and all
figures were produced using R v.3.5.1 (R Development Core Team, Vienna, Aus-
tria), RStudio (v1.1447), ggplot2 (v3.3.2), ggfortify (v0.4.11), corrplot (v0.84) and
GraphPad Prism v9.0.0 (GraphPad Software, San Diego, California, USA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Data and code have also been uploaded to a
data repository and are freely available at https://dataverse.harvard.edu/dataverse/
BlantyreCOVID. We have specifically cited links to clinical52, diagnostic54 and
immunological56 data sets and code within the “Methods” section. Source data are
provided with this paper.
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